In phase II studies with neratinib monotherapy in patients with HER2+ breast cancer, the objective response rate was 24% in trastuzumab-refractory patients and 56% in trastuzumab-naive patients [14]. The gene discussed is ERBB2; the disease is breast carcinoma.